Abacavir International Brand


INDICATIONS AND DOSE

INDICATIONS AND DOSE:

HIV infection in combination with other antiretroviral drugs.
BY MOUTH.
Adult: 600 mg daily in 1–2 divided doses


HIV load greater than 100 000 copies/mL . patients at high risk of cardiovascular disease (especially if 10-year cardiovascular risk greater than 20%)


Appendix 1: abacavir

SIDE-EFFECTS

Very rare Stevens-Johnson syndrome. toxic epidermal necrolysis
Frequency not known Hypersensitivity reactions

SIDE-EFFECTS, FURTHER INFORMATION

Hypersensitivity reactions Life-threatening hypersensitivity reactions reported—characterised by fever or rash and possibly nausea, vomiting, diarrhoea, abdominal pain, dyspnoea, cough, lethargy, malaise, headache, and myalgia; less frequently mouth ulceration, oedema, hypotension, sore throat, acute respiratory distress syndrome, anaphylaxis, paraesthesia, arthralgia, conjunctivitis, lymphadenopathy, lymphocytopenia and renal failure; rarely myolysis; laboratory abnormalities
may include raised liver function tests and creatine kinase; symptoms usually appear in the first 6 weeks, but may occur at any time.610 Viral infection BNF 74 Infection 5 Discontinue immediately if any symptom of hypersensitivity develops and do not rechallenge (risk of more severe hypersensitivity reaction); discontinue if hypersensitivity cannot be ruled out, even when other
diagnoses possible—if rechallenge necessary it must be carried out in hospital setting; if abacavir is stopped for any reason other than hypersensitivity, exclude hypersensitivity reaction as the cause and rechallenge only if medical assistance is readily available; care needed with concomitant use of drugs which cause skin toxicity.
Gastro-intestinal disturbances More common in children.
Rash More common in children.




International Brands

Sr. #
Brand Name
Dosage Form
Pack Size
Price
Manufacturer
1
ZIAGEN 20mg/ml
Oral Solution sugar-free
240ml
£47.36
ViiV Healthcare UK Ltd
2
ZIAGEN 300mg
Tablet
60 Tablet
£177.60
ViiV Healthcare UK Ltd


Reference:
BNF 74, Page No. 610

No comments:

Post a Comment